0
0
May 15, 2025
A longstanding question in respiratory medicine-can chronic asthma truly be reversed?-is once again at the forefront of clinical debate, fueled by recent advances in biological therapies and a deeper understanding of asthma’s complex inflammatory mechanisms.
Shifting the Goalposts: From Control to Remission
Traditionally, asthma has been considered a chronic, lifelong condition, with treatment focused on symptom control and prevention of exacerbations. However, new research suggests the possibility of not just controlling, but potentially reversing the progression of the disease in some patients. This has prompted experts to reconsider whether sustained reversibility-restoring and maintaining normal lung function-should be a primary treatment goal or simply a marker of effective disease management.
Defining Remission and Reversibility
Clinical remission in asthma is defined as the absence of symptoms and exacerbations for at least 12 months, even without medication. Complete remission, a more ambitious target, requires normalized lung function and the absence of airway inflammation. While biologic therapies have made clinical remission more common, complete remission remains elusive for many, largely due to irreversible structural changes in the airways known as remodeling.
The Role of Inflammatory Phenotypes
A major challenge in asthma management is the dynamic nature of inflammatory phenotypes. The Spanish MEGA study found that inflammatory profiles in asthma patients can shift over time, necessitating regular reassessment and individualized treatment adjustments. For instance, only about 61% of patients maintained their initial high T2 phenotype classification after two years, underscoring the need for adaptable therapeutic strategies.
New Insights Into Airway Damage
Groundbreaking research from King’s College London has identified a previously overlooked mechanism: repeated bronchoconstriction leads to crowding and extrusion of airway epithelial cells, causing lasting damage and perpetuating inflammation. While existing treatments do not prevent this damage, experimental agents like gadolinium have shown promise in animal models, potentially opening the door to therapies that could halt or even reverse airway remodeling.
Biological Therapies: A Turning Point
Biologic drugs such as omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab are transforming the treatment landscape for severe asthma, particularly in patients with type 2 inflammation. These targeted therapies have enabled many patients to achieve sustained improvements in lung function and reduced reliance on corticosteroids. Ongoing trials, including the PrecISE study, are investigating whether these therapies can induce long-term reversibility in refractory cases.
Reevaluating Short-Acting Beta-2 Agonists (SABAs)
The SABINA study, the largest real-world analysis of asthma medication use, highlighted the risks of over-reliance on SABAs for symptom relief. Excessive SABA use is linked to poor disease control and higher mortality, prompting new guidelines that recommend combining inhaled corticosteroids with long-acting beta-agonists for both maintenance and relief.
Advances in Diagnosis and Monitoring
Recent updates in diagnostic criteria and techniques, such as serial spirometry and refined bronchodilator response thresholds, have improved the ability to detect reversibility and remission, especially in patients with near-normal lung function. These advances enable more personalized and proactive asthma management.
Looking Ahead
While the prospect of reversing chronic asthma remains challenging-especially in the presence of established airway remodeling-experts agree that the integration of advanced therapies, personalized monitoring, and a deeper understanding of disease mechanisms offers new hope. The ultimate goal: not just to control asthma, but to achieve sustained remission, and, for some, perhaps even reversal.
Disclaimer:
This article is for informational purposes only and is based on current research and expert opinion as reported by Medscape. It should not be interpreted as medical advice. Patients should consult their healthcare provider for diagnosis and treatment of asthma or any other medical condition.
Citations:
